Dermatology

Dermatology physician assistants review the laboratory and monitoring requirements for TYK2 inhibitors deucravacitinib.

These data highlight the frequency of adverse events with narrow-band UVB phototherapy and concomitant therapy.

This analysis was conducted to address the fact that, while there are various acne specific instruments to assess quality of life domains, none exist to focus on all of the domains.

This study’s investigators point to the necessity of adapting an antibiotic stewardship program for acne treatment, with evaluation being done in dermatology practices to assess performance.

In these data, investigators had investigated the international differences in topical AK medication implementation, including links to countries’ different economic statuses.

Experts discuss the landscape of IL therapies for the treatment of psoriasis, highlighting their improved safety and efficacy over prior agents.

Experts discuss the use of TNF blockers in treating plaque psoriasis and their limited but important uses today.

TJ Chao and Kristine Kucera, PA’s go into dept of the recent developments in the systemic oral space of plaque psoriasis.

Physician assistants TJ Chao and Kristine Kucera discuss how the understanding of plaque psoriasis has changed over time and is now considered a systemic disease.

The FDA announcement on bimekizumab’s supplemental Biologics License Application followed the phase 3 BE HEARD I and II studies’ conclusion.

This analysis was conducted to evaluate the burden and disease characteristics of all 3 types of HAE among a set of Canadian patients.

In this review of the top stories in dermatology in March, several were highlighted such as the recent report on benzene in skincare products and the FDA’s approval of spesolimab for generalized pustular psoriasis.

In this interview, Del Rosso expresses his personal views on the recent report of benzene in benzoyl peroxide acne products.

Experts discuss the plethora of treatment options for psoriasis, including topicals, oral therapies, phototherapy, and biologics.

Dermatology physician assistants are talking about the evolving role of their profession in taking care of patients with plaque psoriasis.

A patient shares her journey to the diagnosis of generalized pustular psoriasis (GPP) and her care with dermatologist Dr Scott Boswell.

Advances practice providers TJ Chao, MPAS, PA-C and Kristine Kucera, PA-C, MPAS, DHS discuss the recent development in the treatment landscape of plaque psoriasis.

Chovatiya spoke in this post-AAD interview to some of the major takeaways in psoriasis research, highlighting deucravacitinib, bimekizumab, and other therapies.

Following this analysis, the conclusions provide more information on the views of potential dermatology patients on the future of their own medical images by artificial intelligence systems.

An expert in dermatology provides insight on approaching treatment in patients with plaque psoriasis who have a low BSA involvement, but with symptoms that present in difficult-to-treat areas.

Dr April W. Armstrong comments on patient selection for oral systemic treatments for plaque psoriasis management.

The FDA identified high concentration of lidocaine across marketed, over-the-counter topical products from 6 different companies.

In this analysis from the UK, the DDPS led to improved pathway management which also achieved lower service demand and smaller waiting lists for dermatologists.

This segment of Cohen’s interview from AAD covered the other talk given by Cohen titled ‘Knowing Lichenoid Dermatoses: Common Pathways and Treatments.’

April W. Armstrong, MD, MPH, shares her experience using oral systemic treatments in clinical practice for the management of plaque psoriasis.